GLP-1 therapy addresses not only weight reduction but also helps regulate blood sugar patterns, which becomes increasingly relevant as insulin sensitivity naturally declines after age 30
Digestive issues like nausea and bloating
However, Tesamorelin has more clinical evidence specifically for visceral fat reduction and is FDA-approved for this application
In addition, GLP-1RAs, reduce pancreatic islet -cell apoptosis, stimulate the proliferation and differentiation of -cells, and decrease body weight by suppressing food intake in patients with T2DM [8, 41,42,43]
Importantly, this inhibition may not affect the antioxidative properties of FOXO4
Label Clearly: Label the vial with the date and concentration